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Fibroblast growth factor 21 (FGF21) is a recently
discovered metabolic regulator. Exogenous FGF21
produces beneficial metabolic effects in animal
models; however, the translation of these observa-
tions tohumanshasnotbeen tested.Here,westudied
the effects of LY2405319 (LY), a variant of FGF21, in a
randomized, placebo-controlled, double-blind proof-
of-concept trial in patients with obesity and type 2
diabetes. Patients received placebo or 3, 10, or
20 mg of LY daily for 28 days. LY treatment produced
significant improvements in dyslipidemia, including
decreases in low-density lipoprotein cholesterol and
triglyceridesand increases in high-density lipoprotein
cholesterol and a shift to a potentially less athero-
genic apolipoprotein concentration profile. Favorable
effects on bodyweight, fasting insulin, and adiponec-
tin were also detected. However, only a trend toward
glucose lowering was observed. These results indi-
cate that FGF21 is bioactive in humans and suggest
that FGF21-based therapies may be effective for the
treatment of selected metabolic disorders.
INTRODUCTION
Recent projections indicate that more than 550 million people
will be afflicted with diabetes by 2030 (Whiting et al., 2011).
Most patients with diabetes have other features of the metabolic
syndrome—defined by the presence of three or more of the
following signs and symptoms: glucose intolerance, abdominal
obesity, hypertriglyceridemia, low high-density lipoprotein
cholesterol (HDL-C) levels, and hypertension (Moller and Kauf-
man, 2005). A limitation of currently available drug classes for
the treatment of risk factors associated with the metabolic syn-
drome is that no single agent (e.g., statin, fibrate, or metformin)
is able to address more than one comorbid condition. Thus,
many individual therapies are usually prescribed in combination,
leading to tolerability issues, poor patient compliance, and sub-
optimal outcomes, all of which provide an incentive for
continuing the search for new therapeutic approaches.
Fibroblast growth factor 21 (FGF21) is a recently identified
circulating protein that regulates insulin sensitivity along withCell Melipid and energy metabolism. We initially discovered FGF21 in
a glucose uptake screen in 3T3-L1 adipocytes (Kharitonenkov
et al., 2005) and subsequently demonstrated that the administra-
tion of FGF21 to obese diabetic rodents markedly improved
hyperglycemia, lowered elevated triglycerides (TGs), and
reduced body weight (Coskun et al., 2008; Kharitonenkov
et al., 2005; Wente et al., 2006). Importantly, the administration
of exogenous FGF21 to obese diabetic rhesus monkeys pro-
moted improvements in glucose, body weight, and circulating
lipids (Kharitonenkov et al., 2007). Themetabolic effects of native
FGF21 or its derivatives and mimetics have also been replicated
by other investigators in rodents and nonhuman primates (Foltz
et al., 2012; Hecht et al., 2012; Mu et al., 2012; Smith et al.,
2013; Ve´niant et al., 2012; Xu et al., 2009). As shown in rodents,
the mechanisms underlying the pleiotropic actions of FGF21
include enhanced total body insulin sensitivity (Berglund et al.,
2009) and improved pancreatic islet b cell function (Wente
et al., 2006) along with the suppression of islet glucagon secre-
tion (Kharitonenkov et al., 2005), reduced hepatic lipogenesis,
and the induction of energy expenditure via brown fat activation
(Coskun et al., 2008; Fisher et al., 2012; Kharitonenkov et al.,
2005). At a molecular level, FGF21 interacts with the FGF recep-
tor 1c only in tissues expressing the cofactor Klotho b (Adams
et al., 2012a). Although most of the effects of FGF21 were
discovered empirically in the previously described laboratory
experiments, the Klotho b-dependent tissue specificity is consis-
tent with the predominant effects of FGF21 occurring in liver and
adipose tissue.
There are important potential differences between the physio-
logic role(s) of FGF21 and the pharmacologic effects of exoge-
nous FGF21 (Kliewer and Mangelsdorf, 2010; Angelin et al.,
2012). However, some aspects of FGF21 pharmacology appear
related to its potential physiology. For example, the phenotype of
increased adipose mass in FGF21 knockout mice is generally
consistent with the reported effects of FGF21 overexpression
in transgenic mice or dosing at pharmacological levels (Adams
et al., 2012b; Badman et al., 2009; Hotta et al., 2009; Kharito-
nenkov et al., 2005). In addition, treatment ofmicewith lowdoses
of FGF21, resulting in plasma concentrations only 30% to 50%
above endogenous levels, results in effects that are similar to
(albeit attenuated) higher doses. Thus, the effect of increasing
adiponectin levels, a marker of FGF21 action on adipose tissue,
occurs with a clear dose response ranging frompronouncedwith
higher pharmacological doses to more modest at doses
that achieve levels found in the physiological range (Holland
et al., 2013). This relationship is also consistent with datatabolism 18, 333–340, September 3, 2013 ª2013 Elsevier Inc. 333
Figure 1. Trial Profile
Numbers of subjects initially screened and sub-
sequently randomized to each of four treatment
groups are depicted. Subject disposition (number
of subjects who discontinued treatment or
completed the study) are also shown.
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knockout mice (Holland et al., 2013; Lin et al., 2013).
The beneficial pharmacology observed in preclinical models
indicated that FGF21 and its analogs or mimetics hold promise
as innovative therapeutics and may represent a future class of
‘‘glucose plus’’ medicines for treating metabolic disorders
(Moller, 2012). Toward that end, drug discovery efforts yielded
LY2405319 (LY), an investigational FGF21 variant suitable for
early-phase clinical development. LY is indistinguishable from
native human FGF21 in cell-based, rodent, and nonhuman
primate assays with respect to potency, selectivity, and multiple
measures of biological activity and efficacy (Adams et al., 2013a;
Kharitonenkov et al., 2013).
The goals of early clinical studies were to characterize LY for
safety and pharmacokinetics in healthy volunteers and to assess
its potential effects for ameliorating abnormalities commonly
associated with type 2 diabetes (T2DM). Initial clinical experi-
ence with LY included a single ascending dose study in 19
healthy men who received doses ranging from 0.6 to 30 mg
and a multiple ascending dose study in 32 men and women
who received doses of LY ranging from 1 to 20 mg daily for
7 days. There was a statistically significant dose-dependent
increase in HDL-C and a decrease in TGs in the 7-day study
(data not shown). There were no serious adverse events or
clinically meaningful safety concerns in either study. These
investigations provided safety, tolerability, pharmacokinetic,
and limited pharmacodynamic data to support a 28-day phase
1b proof-of-concept trial in obese subjects with T2DM-exploring
doses of LY up to 20 mg per day. The translational medicine
study described here reports pharmacodynamic metabolic
effects of an FGF21-derived molecule in humans.
RESULTS
Patient Characteristics
Of the 178 subjectswho signed informed consent and underwent
screening procedures, 47 met the inclusion criteria and were
randomly assigned to treatment, 46 received at least one dose
of the study drug, and 38 completed the study (Figure 1). Clinical
characteristics of the 46 individuals receiving the study drug are
shown in Table 1. Patients had been diagnosedwith T2DM for an
average of 7.4 years prior to enrollment, 43 of the 46 were
receiving metformin, and 11 were treated with a statin. Baseline334 Cell Metabolism 18, 333–340, September 3, 2013 ª2013 Elsevier Inc.characteristics were similar across treat-
ment groups, the exception being fasting
glucose, which was included as a covari-
ate variable in the statistical analysis.
LY2405319 Plasma Exposure
LY plasma exposure was measured at
several time points on day 28 of the study,0 (predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hr after dose
administration. Average steady-state circulating plasma con-
centrations of LY on day 28 were 17.5 ± 4 ng/ml in subjects
who received the 3 mg daily dose, and levels were 67.3 ±
25 ng/ml and 150 ± 49 ng/ml in subjects treated with 10 and
20 mg, respectively.
Effects on Plasma Lipids and Lipoproteins
Table 2 provides a summary of metabolic and glycemic param-
eters for each of the four treatment groups at baseline and after
28 days of daily subcutaneous injections of LY or placebo. Final
low-density lipoprotein cholesterol (LDL-C) concentrations were
unchanged in the 3 mg treatment group, whereas reductions of
29.5% and 20.2% were observed for the 10 and 20 mg groups,
respectively (Table 2). Significant reductions in LDL-C occurred
as early as day 7, the maximal lowering effect of LY occurring
between study days 14 and 21 (Figure 2). Relative to baseline,
significant mean decreases in fasting TG levels were observed
as early as day 2 for all three dosing groups, and maximal TG
lowering was observed between days 2 and 7 (Figure 2). These
reductions were maintained for the duration of the treatment
period andwere significantly different from baseline and placebo
at the 10 and 20mg dose levels (Table 2; Figure 2). In comparison
to baseline and placebo values, total cholesterol concentrations
were also lowered in patients treated with 10 (19.2%) or 20 mg
(15.4%) of LY (Table 2). Additionally, an increase of 15% to
20% in HDL-C occurred across all three dose groups (Table 2).
These improvements in dyslipidemia were accompanied by a
shift to a less atherogenic apolipoprotein (apo) profile. In com-
parison to baseline and placebo, both 10 and 20 mg dose levels
of LY reduced apoC-III by approximately 35%, whereas apoB
was reduced by 25.1%and 21.6%, respectively (Table 2). ApoAII
was also decreased (18.3%) from baseline and placebo values
in the 20 mg treatment group (Table 2).
Effects on BodyWeight, Glucose, and Other Parameters
Reductions in mean body weight relative to baseline were signif-
icant for the 10 (1.75 kg) and 20mg (1.49 kg) dose groups, the
maximal effect being observed at the 10 mg dose level (Table 2).
Notably, these changes were smaller in comparison to placebo
and did not reach statistical significance for either dose group
(10 mg [p = 0.1011] and 20 mg [p = 0.1211]). Regardless of
dose level, the least squares mean difference in the change
Table 1. Subject Baseline Demographics
Treatment Group Placebo 3 mg 10 mg 20 mg Overall
Subjects
Randomized
10 11 10 15 46
Female 6 4 3 7 20
Male 4 7 7 8 26
Origin - White 10 11 10 13 44
Origin - African
American
0 0 0 1 1
Origin - Asian 0 0 0 1 1
Metformin use 10 11 9 13 43
Duration T2DM
(years) (SD)
7.7
(5.9)
9.8
(6.8)
5.0
(2.7)
7.2
(4.6)
7.4
(5.3)
Age (years) (SD) 58.6
(6.3)
56.5
(7.3)
59.6
(9.2)
56.9
(10.2)
57.7
(8.4)
BMI (kg/m2) (SD) 32.7
(3.5)
31.3
(2.8)
33.4
(3.2)
31.5
(4.4)
32.1
(3.6)
Baseline FG
(mg/dl)a (SD)
161.5
(15.9)
179.2
(36.5)
152.8
(30.6)
186.1
(32.4)
171.9
(32.3)
Screening HbA1c
(%) (SD)
7.55
(0.60)
8.30
(1.08)
7.80
(0.89)
8.10
(0.79)
7.96
(0.87)
The table summarizes clinical characteristics of study subjects at
baseline (randomization) by treatment group.
aSignificant difference (p < 0.05) in baseline fasting glucose among the
four treatment arms.
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versus baseline or placebo over the 28-day treatment period
(Table 2). A glucose-lowering trend (p = 0.12) for a dose response
across was observed across LY dose groups (Figure 3). Fasting
insulin levels were significantly reduced in the 20 mg dose group
in comparison to baseline values (Table 2).
Plasma concentrations of adiponectin increased in compari-
son to baseline over the 28-day treatment period for all three
LY dose levels, and the mean change in the 20 mg dose group
was significant in comparison to placebo on day 28 (Table 2; Fig-
ure 3). Adiponectin circulates in one of three forms: as a trimer, in
a low-molecular-weight complex, or in a high-molecular-weight
complex. LY treatment for 28 days at the 20 mg dose level
was sufficient to substantially change the adiponectin complex
distribution. The proportion of high-molecular-weight adiponec-
tin, a potential contributor to the efficacy of thiazlodinedione
insulin sensitizers (Pajvani et al., 2004), increased from
25.0% ± 3.3% at baseline to 39.6% ± 3.9% (p < 0.02). A corre-
sponding decrease was observed for the circulating adiponectin
trimer (45.2% ± 4.3% to 29.0% ± 2.7% of the protein’s popula-
tion [p < 0.02]), whereas an abundance of low-molecular-weight
adiponectin remained unchanged. Significant effects (p < 0.03)
in complex formation were also detectable after 14 days of LY
treatment, albeit with slightly less magnitude.
Finally, concentrations of b-hydroxybutyrate were also
compared to baseline and placebo and were shown to be
elevated in all three LY dose groups on day 28 (Table 2).
Adverse Events
There were three serious adverse events during this study. On
study day 27, one subject in the 20 mg dose group had a severeCell Mereaction, including a drop in blood pressure, urticaria, and
pruritis, requiring treatment with intravenous antihistamines
and corticosteroids. This subject had a drug antibody titer of
1:320 at day 28 and a higher peak titer of 1:1,280 by day 35.
The other two serious adverse events (cholecystitis [day 26]
and optic neuropathy [day 38 after the last dose of study drug])
were assessed by the investigator as related to pre-existing
diseases in the patients.
Three subjects discontinued because of adverse events that
were considered related to treatment: one individual with hyper-
sensitivity, one with elevated liver enzymes, and a third with
injection site reactions, headache, and urticaria that had no
detected antibodies to LY. The majority (94.5%) of the remaining
treatment-emergent adverse events were mild in severity.
Injection-site-related adverse events were the most frequently
reported across all doses but were more prevalent at the 10
and 20 mg dose levels.
Drug antibodies were measured in each patient and were
observed in 20% of placebo-treated patients and in 55%,
80%, and 87% of patients treated with 3, 10, and 20mg, respec-
tively. Titers of R1:32 occurred in no placebo-treated patients
and 9%, 60%, and 47% of patients in the 3, 10, and 20 mg
groups, respectively. Drug antibodies were present in a greater
proportion of patients with injection site reactions but did not
affect pharmacokinetics or pharmacodynamics of LY.
DISCUSSION
This study reports the pharmacology and efficacy of an FGF21-
derived compound administered to human subjects—in this
case, obese patients with T2DM. At the end of the 28-day treat-
ment period, there were statistically and clinically meaningful
effects on lipids and body weight in comparison to baseline. A
dose-dependent trend in the lowering of fasting glucose was
also observed. Although LY is indistinguishable from native
FGF21 in both in vitro and in vivo preclinical laboratory testing
(Adams et al., 2013a; Kharitonenkov et al., 2013), it is important
to emphasize that the effects described in the current report
were pharmacologic and may not reflect the underlying physio-
logic role(s) of FGF21 in humans (Angelin et al., 2012). The mean
concentrations of LY observed in this study increased in a dose-
proportionate manner and ranged from 10- to over 100-fold
greater than previously reported for endogenous FGF21 in
diet-induced obese and leptin-deficient (ob/ob) mice (Hale
et al., 2012) or in humans, including obese patients with T2DM
(Chavez et al., 2009; Angelin et al., 2012). Importantly, plasma
LY levels were also within the range of efficacious exposures
of LY (or human recombinant FGF21) achieved in animal models
(Coskun et al., 2008; Kharitonenkov et al., 2005; Wente et al.,
2006; Kharitonenkov et al., 2013).
The impact of LY treatment on all four lipid parameters (total
cholesterol, LDL, HDL, and TGs) was rapid, occurring as early
as 2 days after the initiation of dosing in the case of fasting
TGs, and appeared to reach a maximum effect within 7 to
21 days. The top end of the explored dose range appeared to
achieve maximum efficacy for lipids, the 10 mg dose providing
effects indistinguishable from those at the 20 mg dose. Promi-
nent reductions in apoCIII may have contributed to TG lowering,
given the known role of apoCIII in the regulation of TG clearancetabolism 18, 333–340, September 3, 2013 ª2013 Elsevier Inc. 335
Table 2. Summary of Change in Metabolic and Glycemic Parameters
Placebo 3 mg 10 mg 20 mg
LDL-C (mmol/l)
Baseline 2.78 2.72 2.35 3.11
Week 4 2.76 2.71 1.66 2.48
LS mean change from baseline
to week 4 (%, SE)
0.751% (6.9)
n = 7
0.099% (6.0)
n = 10
29.5% (7.8)a,b
n = 8
20.2% (4.56)a,b
n = 13
HDL-C (mmol/l)
Baseline 1.02 1.16 1.12 1.13
Week 4 1.00 1.34 1.29 1.35
LS mean change from baseline
to week 4 (%, SE)
2.29% (4.4)
n = 8
15.6% (3.4)a,b
n = 10
15.2% (3.9)a,b
n = 8
19.5% (3.07)a,b
n = 13
Apolipoprotein A2 (g/l)
Baseline 0.347 0.378 0.352 0.351
Week 4 0.326 0.374 0.314 0.286
LS mean change from baseline
to week 4 (%, SE)
6.02% (3.4)
n = 8
1.09% (2.9)
n = 9
10.7% (3.3)b
n = 8
18.3% (2.60)a,b
n = 13
Apolipoprotein B (g/l)
Baseline 1.01 0.855 0.832 1.00
Week 4 1.07 0.873 0.623 0.784
LS mean change from baseline
to week 4 (%, SE)
5.76% (5.0)
n = 8
2.12% (5.3)
n = 10
25.1% (6.5)a,b
n = 7
21.6% (3.99)a,b
n = 13
Apolipoprotein C-III (g/l)
Baseline 0.180 0.123 0.130 0.142
Week 4 0.176 0.104 0.086 0.091
LS mean change from baseline
to week 4 (%, SE)
2.30% (4.5)
n = 7
15.2% (5.2)b
n = 9
34.0% (5.1)a,b
n = 8
35.4% (3.63)a,b
n = 13
Triglycerides (mmol/l)
Baseline 3.13 1.68 1.98 2.14
Week 4 3.20 1.25 1.07 1.18
LS mean change from baseline
to week 4 (%, SE)
2.48% (6.1)
n = 8
25.9% (9.9)b
n = 10
46.2% (9.0)a,b
n = 8
44.6% (6.57)a,b
n = 13
Total cholesterol (mmol/l)
Baseline 5.14 4.72 4.40 5.28
Week 4 5.11 4.82 3.56 4.47
LS mean change from baseline
to week 4 (%, SE)
0.632% (3.6)
n = 8
2.13% (3.5)
n = 10
19.2% (4.2)a,b
n = 8
15.4% (2.76)a,b
n = 13
Glucose, Fasting (mmol/l)
Baseline 8.97 9.95 8.49 10.3
Week 4 9.14 9.75 8.11 9.75
LS mean change from baseline
to week 4 (mmol/l, SE)
0.176 (0.58)
n = 8
0.195 (0.52)
n = 10
0.372 (0.59)
n = 8
0.581 (0.463)
n = 13
Insulin (pmol/l)
Baseline 65.7 67.4 88.4 88.4
Week 4 62.8 58.6 55.1 52.3
LS mean change from baseline
to week 4 (pmol/l, SE)
2.85 (19.5)
n = 8
8.77 (17.4)
n = 10
33.2 (19.6)
n = 8
36.0 (15.3)b
n = 13
Adiponectin (ng/ml)
Baseline 4160 6230 5020 6830
Week 4 4610 8080 7930 12500
LS mean change from baseline
to week 4 (ng/ml, SE)
458 (976)
n = 8
1850 (869)b
n = 10
2910 (972)b
n = 8
5650 (784)a,b
n = 12
(Continued on next page)
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Table 2. Continued
Placebo 3 mg 10 mg 20 mg
b-Hydroxybutyrate (mg/dl)
Baseline 1.24 1.17 1.33 1.13
Week 4 0.868 2.08 2.18 2.32
LS mean change from baseline
to week 4 (mg/dl, SE)
0.372 (0.39)
n = 8
0.906 (0.35)a,b
n = 10
0.852 (0.39)a,b
n = 8
1.19 (0.306)a,b
n = 13
Weight (kg)
Baseline 88.7 85.4 95.6 86.3
Week 4 88.5 84.7 93.8 84.8
LS mean change from baseline
to week 4 (kg, SE)
0.229 (0.62)
n = 8
0.679 (0.56)
n = 10
1.75 (0.65)b
n = 8
1.49 (0.492)b
n = 13
The table summarizesmean (±SEM) values for several measuredmetabolic parameters by treatment group at baseline versus study endpoint (week 4).
In addition, the percent change from baseline for each measured parameter is also noted. LS, least squares.
ap < 0.05 in comparison to placebo.
bp < 0.05 in comparison to baseline.
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also reduced as expected on the basis of the observed LDL-
lowering effect. Notably, changes in lipid parameters were very
similar to effects we have previously reported after the adminis-
tration of FGF21 or LY to obese rhesus monkeys with dyslipide-
mia (Adams et al., 2013a; Kharitonenkov et al., 2007).
Body weight was reduced over the 28-day treatment period
(Figure 3). As with the lipids, 10 mg seemed to be the maximum
effective dose in this study. Given that body weight typically
takes at least 6 months to reach a maximum reduction, whether
due to pharmacology or lifestyle intervention, it is possible that
the 10 and 20 mg doses would diverge with longer treatment.
In animal models, FGF21 administration lowers body weight
via increased metabolic rate and without suppressing food
intake (Coskun et al., 2008). Given that neither caloric intake
nor energy expenditure were measured in the current study, it
is not yet possible to assess the mechanisms underlying weight
loss in humans. However, significant increases in b-hydroxybu-
tyrate are suggestive of LY-enhanced fatty acid oxidation, thus
implying that reduced body weight may be related to an increase
in total body energy expenditure. Future clinical studies with
FGF21-based therapies should assess mechanisms that may
underlie the weight loss effect; these could include appetite
(visual analog scale), food intake, resting metabolic rate, body
composition, and fat distribution.
The LY effects on glucose were not as robust as expected on
the basis of studies in both rodent and nonhuman primateCell Memodels of T2DM (Adams et al., 2013a; Kharitonenkov et al.,
2005; Kharitonenkov et al., 2007). Although decreases from
baseline in fasting glucose were larger for all doses of LY in com-
parison to placebo, none of these changes were statistically
significant. The time course of glucose response differed from
that of the lipids, showing no evidence of being different from
placebo or dose-dependent until the 21- and 28-day assess-
ments. Although baseline glucose was included as a covariate
in the final statistical analysis, given the small sample size, base-
line differences may have confounded the interpretation of the
glucose data. Further studies that incorporate longer periods
of treatment and alternative patient populations (e.g., with
impaired fasting glucose or T2DMwith varying degrees of hyper-
glycemia at baseline) may be needed in order to elucidate the
true potential glycemic effects of exogenous FGF21 treatment.
Interestingly, a prominent reduction in mean fasting insulin
levels was observed—this replicates the effects of FGF21
demonstrated earlier in rodents and nonhuman primates
(Kharitonenkov et al., 2005; Kharitonenkov et al., 2007). As
with lipids and body weight, fasting insulin showed a dose-
dependent lowering at 28 days with a maximum effect observed
with the 20 mg dose. This finding is consistent with a potential
improvement in insulin sensitivity, although direct measures of
insulin action were not evaluated in this study.
Plasma adiponectin levels were also increased in a dose-
dependent manner, which was consistent with the ability of
FGF21 to robustly induce adiponectin levels in animal modelsFigure 2. Effect of LY2405319 on Trigly-
cerides and LDL-Cholesterol
Time course of mean (±SEM) change from
baseline in fasting plasma TGs (A) and LDL-C (B).
*p < 0.05 from baseline, yp < 0.05 from placebo.
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Figure 3. Effect of LY2405319 on Body
Weight and Selected Metabolic Parameters
Mean change from baseline (±SEM) in fasting
glucose, insulin, adiponectin, and body weight.
*p < 0.05 from baseline, and yp < 0.05 from
placebo.
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Kharitonenkov et al., 2007). Recently, it has been demonstrated
that adiponectin plays an important role in the propagation of the
metabolic effects of FGF21 (Holland et al., 2013; Lin et al., 2013).
Importantly, low adiponectin levels in humans are correlatedwith
obesity and insulin resistance (Rasmussen-Torvik et al., 2012),
and treatment of rodents with exogenous adiponectin has
been shown to augment insulin action (Berg et al., 2001; Turer
and Scherer, 2012). LY also substantially changed adiponectin
complex distribution, increasing the proportion of high-
molecular-weight adiponectin. Importantly, increasing levels of
high molecular weight adiponectin per se have been identified
as a correlate of human efficacy in the case of antidiabetic
thiazolidinedione treatment (Pajvani et al., 2004).
Interestingly, relative to lean normal subjects, circulating levels
of FGF21 are reportedly elevated (by 1.5- to 2.0-fold) in patients
with obesity and T2DM (Chen et al., 2008; Dushay et al., 2010). It
is also apparent that plasma FGF21 levels are more prominently
increased in patients with nonalcoholic fatty liver disease
(Dushay et al., 2010). These observations have led to the hypoth-
esis that obesity, fatty liver disease, and T2DM may be states of
relative FGF21 ‘‘resistance.’’ Nevertheless, treatment of obese,
hyperglycemic, ob/obmicewith FGF21 can still normalize hyper-
glycemia despitemarkedly elevated endogenous FGF21 levels in
these animals (Hale et al., 2012; Kharitonenkov et al., 2005). The
intrasubject variability of circulating FGF21 levels in humans has
also been reported to be as great as 100-fold (Ga¨lman et al.,
2008; Angelin et al., 2012). Given this, as well as the fact that
obesity and T2DM are clearly heterogeneous syndromes rather
than discrete disorders (Drong et al., 2012), it will be important
in larger future investigations to determine which patient charac-
teristics are potentially associatedwithmore favorablemetabolic
responses to FGF21-based therapy. Given that endogenous
FGF21 levels were not measured in the present study, future
human studies should also determinewhether this key parameter338 Cell Metabolism 18, 333–340, September 3, 2013 ª2013 Elsevier Inc.is a predictor of response and the extent
to which endogenous levels might be
modulated by FGF21-based therapies.
Treatment with LY was generally well
tolerated. However, skin rash and hyper-
sensitivity in two 20 mg subjects, as well
as injection site reactions in several other
patients, were notable in this study. We
speculate that these effects are unrelated
to FGF21 action per se but might repre-
sent specific aspects of the LY molecule
or the formulation used in this study.
Recent reports have highlighted impaired
growth hormone signaling and bone loss
as two possible safety concerns that
pertain to the future development andutility of FGF21-based therapies. Transgenic mice which overex-
press FGF21 exhibit moderate growth retardation and evidence
of growth hormone resistance (Inagaki et al., 2008). Another
recent report also shows that FGF21 transgenic mice have
reduced bone density, and FGF21 treatment of mice also
produced a similar effect (Wei et al., 2012). Neither bone
biomarkers nor bone mineral density were evaluated in the
current study and would most likely be uninformative given the
study size and duration. Nevertheless, these recently reported
findings in rodentsmerit further investigation in any future human
studies of FGF21 or related analogs.
In summary, daily administration of LY, a human FGF21
analog, provided clear evidence of clinically meaningful effects
on several metabolic comorbidities associated with T2DM.
Although maximum efficacy appeared to be rapidly achieved
within the LY dose range studied for lipids, a maximally effica-
cious dose was not clearly established for other key endpoints,
such as adiponectin and fasting glucose. Thus, the exploration
of higher doses and longer treatment periods would be
necessary in order to assess the full range of LY effects and
the potential to achieve meaningful antidiabetic efficacy. Robust
effects on fasting insulin were consistent with potential
insulin sensitization. Prominent increases in adiponectin, high-
molecular-weight adiponectin and b-hydroxybutyrate also
indicate that specific pathways which are modulated by FGF21
in rodents are also operative in humans and are likely contribu-
tors to secondary metabolic benefits of FGF21.
EXPERIMENTAL PROCEDURES
Study Design and Patients
Eligible subjects were between the ages of 18 and 75 years old (inclusive) with
a body mass index (BMI) of 25 to 40 kg/m2 (inclusive) and had a diagnosis of
T2DM prior to screening on the basis of the disease diagnostic criteria (World
Health Organization) classification, and a fasting C peptide >1 ng/ml. Patients
were ineligible if they used insulin, thiazolidinediones, dipeptidyl-peptidase IV
Cell Metabolism
Metabolic Effects of an FGF21 Analog in Humansinhibitors, or exenatide during the previous 3 months or had recently experi-
enced severe hypo- or hyper-glycemia. Patients who were found eligible for
the study by initial screening procedures but were receiving metformin and
one additional oral antidiabetic medication were removed from treatment of
the second medication and rescreened after a minimum 14-day washout
period to confirm that eligibility criteria were met prior to randomization.
Patients were required to have HbA1c values of 7% to 10%, the exception
being those who were receiving metformin and an additional oral antidiabetic
medication, in which case HbA1c values were required to be 6.5% to 9.5% in-
clusive in order to account for the inevitable rise in glucose that accompanies
the discontinuation of a second agent. Females were required to be surgically
sterilized or postmenopausal. All individuals exhibited acceptable results on
clinical laboratory tests, vital signs, and electrocardiogram at screening.
All patients gave written informed consent, and the protocol was approved
by the local ethics committee and institutional review boards at each partici-
pating center. This study complied with the Declaration of Helsinki and its
amendments and was performed in accordance with Good Clinical Practice
guidelines. The trial was registered at http://clinicaltrials.gov (#NCT01869959).
Randomization and Masking
Patients were randomly assigned in an equal proportion to one of the four
treatment groups. Individuals were stratified at the site level on the basis of
treatment (assigned dose level), metformin treatment (yes or no), and fasting
glucose level. Subjects and investigators were masked to drug versus
volume-matched placebo at every LY dose level.
Procedures
After the initial screening, patients were randomized to the study drug (3, 10, or
20 mg of LY) or placebo and continued this treatment for 28 days. Subcutane-
ous injections were administered daily, and volumes of placebo were chosen
to match the volumes of the three doses of LY. At baseline and treatment days
2, 7, 14, 21, and 28, body weight was measured, and fasting blood samples
were collected and analyzed for lipid and glycemic parameters. Throughout
the treatment and followup periods, patients were to continue on their current
diet and exercise regimen in addition to their stable metformin and/or statin
treatment (where applicable).
Analytical Methods
LY concentrations were analyzed with an LY antibody and a validated ELISA
with a lower limit of quantification of 250 pg/ml. Insulin was measured by an
immunoenzymatic assay (Beckman Coulter). Glucose was determined by a
hexokinase method (Roche Diagnostics). Total cholesterol and TGs were
measured with Center for Disease Control methods with the use of a Roche
Modular Analyzer (performed by Covance Central Laboratory Services). Direct
HDL-C and LDL-Cwere determined enzymatically (Roche). b-hydroxybutyrate
was determined enzymatically (ARUP Laboratories). ApoAI, apoAII, and apoC-
III were determined by immunonephelometry (Siemens Healthcare Diagnos-
tics) and immunoturbidimetry (Kamiya Biomedical), respectively. ApoB was
determined by nephelometry (Roche). Total adiponectin was determined by
ELISA (R&D Systems). Adiponectin complex distribution was assessed with
a gel filtration and a fast-protein-liquid chromatography-based assay followed
by western blotting as previously reported (Schraw et al., 2008).
Statistical Methods
Sample size calculations were based on the interpatient variability of fasting
glucose observed in similar internal studies (SD approximately 0.58 mmol/l).
It was determined that eight patients per group would provide at least 90%
power (one-sided alpha of 0.05) to detect an average fasting glucose
decrease of 0.83 mmol/l (assuming the highest dose achieves this effect) in
comparison to placebo by using a linear trend test. Pharmacodynamic
analyses were conducted on all data from all evaluable patients. Safety
analyses were conducted for all enrolled and randomized patients under the
intent-to-treat principle.
For each measured parameter, a mixed effect linear model was used with
change from baseline as the response variable, treatment, day, and treatment
by day interaction as fixed effects, baseline value as covariate, and subject as
random effect. Pairwise treatment comparisons between LY dose groups and
placebo were performed for each day. The 90% confidence intervals and theCell MeWe calculated SEM differences change from baseline in comparison placebo
group using the within-subject error and degrees of freedom derived from the
mixed effect model. Statistical significance was claimed when p < 0.05 from a
two-sided test.
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